Indaptus Therapeutics (NASDAQ:INDP) Announces Earnings Results, Beats Expectations By $1.55 EPS

Indaptus Therapeutics (NASDAQ:INDP) posted its earnings results on Thursday. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($1.57) by $1.55, Zacks reports.

Indaptus Therapeutics Stock Performance

NASDAQ:INDP traded up $0.01 during mid-day trading on Friday, reaching $1.07. The stock had a trading volume of 94,768 shares, compared to its average volume of 451,611. The stock has a market capitalization of $121.17 million, a P/E ratio of -0.07 and a beta of 1.18. The firm has a 50 day moving average price of $2.57 and a two-hundred day moving average price of $2.22. Indaptus Therapeutics has a one year low of $0.92 and a one year high of $8.57.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wall Street Zen raised Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is owned by hedge funds and other institutional investors.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.